Business Development
Unigene is the Peptide Development Partner of Choice:
Peptide therapeutics need a more patient-friendly delivery option
SOLUTION: UNIGENE'S ORAL DELIVERY
UNIGENE'S PROPRIETARY TECHNOLOGY:
- Overcomes the need for injection
- Reduces degradation in the GI tract
- Increases absorption through intestinal membranes
HOW IT WORKS:
ADVANTAGES:
- Positive Phase 3 data validates technology
- Most advanced oral peptide in development
- Up to 25% absolute bioavailability
- Not impacted by food or liquid intake
- Less API required compared to competitor
- Patent protection to 2028
UNIGENE'S ORAL DELIVERY TECHNOLOGY OFFERS:
- Lifecycle management for currently approved peptides
- Greater market potential for niche peptides
- Increased commercial viability for development stage peptides
ORAL DELIVERY CORRELATION AMONG THREE SPECIES:
FEASIBILITY PATHWAY:
Small Animal Preclinical Models
- Intraduodenal administration of formulated peptide
- Blood samples tested for peptide PK profile
Large Animal Preclinical Models
- Enteric-coated solid dosage capsules
- Peptide bioavailability evaluated
- The dog model is the best predictor of bioavailability in humans using Unigene's proprietary oral formulation
DOG DATA DIRECTLY CORRESPONDS WITH HUMAN:
Feasibility can be completed within 3 months
